7xi7

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (17:54, 29 November 2023) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 7xi7 is ON HOLD until Paper Publication
+
==Human dihydrofolate reductase complexed with P39==
 +
<StructureSection load='7xi7' size='340' side='right'caption='[[7xi7]], [[Resolution|resolution]] 1.65&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[7xi7]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7XI7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7XI7 FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.65&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4RI:6-hexyl-5-phenyl-pyrimidine-2,4-diamine'>4RI</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7xi7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7xi7 OCA], [https://pdbe.org/7xi7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7xi7 RCSB], [https://www.ebi.ac.uk/pdbsum/7xi7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7xi7 ProSAT]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/DYR_HUMAN DYR_HUMAN] Defects in DHFR are the cause of megaloblastic anemia due to dihydrofolate reductase deficiency (DHFRD) [MIM:[https://omim.org/entry/613839 613839]. DHFRD is an inborn error of metabolism, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency. Clinical features include variable neurologic symptoms, ranging from severe developmental delay and generalized seizures in infancy, to childhood absence epilepsy with learning difficulties, to lack of symptoms.<ref>PMID:21310276</ref> <ref>PMID:21310277</ref>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/DYR_HUMAN DYR_HUMAN] Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.<ref>PMID:21876188</ref> <ref>PMID:12096917</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Pyrimethamine (Pyr), a known dihydrofolate reductase (DHFR) inhibitor, has long been used to treat toxoplasmosis caused by Toxoplasma gondii (Tg) infection. However, Pyr is effective only at high doses with associated toxicity to patients, calling for safer alternative treatments. In this study, we investigated a series of Pyr analogues, previously developed as DHFR inhibitors of Plasmodium falciparum bifunctional DHFR-thymidylate synthase (PfDHFR-TS), for their activity against T. gondii DHFR-TS (TgDHFR-TS). Of these, a set of compounds with a substitution at the C(6) position of the pyrimidine ring exhibited high binding affinities (in a low nanomolar range) against TgDHFR-TS and in vitro T. gondii inhibitory activity. Three-dimensional structures of TgDHFR-TS reported here include the ternary complexes with Pyr, P39, or P40. A comparison of these structures showed the minor steric strain between the p-chlorophenyl group of Pyr and Thr83 of TgDHFR-TS. Such a conflict was relieved in the complexes with the two analogues, P39 and P40, explaining their highest binding affinities described herein. Moreover, these structures suggested that the hydrophobic environment in the active-site pocket could be used for drug design to increase the potency and selectivity of antifolate inhibitors. These findings would accelerate the development of new antifolate drugs to treat toxoplasmosis.
-
Authors: Vanichtanankul, J., Saeyang, T., Kamchonwongpaisan, S., Yuvaniyama, J., Yuthavong, Y.
+
Structural Insight into Effective Inhibitors' Binding to Toxoplasma gondii Dihydrofolate Reductase Thymidylate Synthase.,Vanichtanankul J, Yoomuang A, Taweechai S, Saeyang T, Pengon J, Yuvaniyama J, Tarnchompoo B, Yuthavong Y, Kamchonwongpaisan S ACS Chem Biol. 2022 Jun 17. doi: 10.1021/acschembio.1c00627. PMID:35715223<ref>PMID:35715223</ref>
-
Description: Human dihydrofolate reductase complexed with P39
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Yuthavong, Y]]
+
<div class="pdbe-citations 7xi7" style="background-color:#fffaf0;"></div>
-
[[Category: Yuvaniyama, J]]
+
== References ==
-
[[Category: Saeyang, T]]
+
<references/>
-
[[Category: Vanichtanankul, J]]
+
__TOC__
-
[[Category: Kamchonwongpaisan, S]]
+
</StructureSection>
 +
[[Category: Homo sapiens]]
 +
[[Category: Large Structures]]
 +
[[Category: Kamchonwongpaisan S]]
 +
[[Category: Saeyang T]]
 +
[[Category: Vanichtanankul J]]
 +
[[Category: Yuthavong Y]]
 +
[[Category: Yuvaniyama J]]

Current revision

Human dihydrofolate reductase complexed with P39

PDB ID 7xi7

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/7xi7"
Personal tools